Journal article
Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Results From the OASIS-5 Trial
Abstract
OBJECTIVES: This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
BACKGROUND: In the OASIS-5 trial, fondaparinux was similar to enoxaparin for short-term efficacy, but reduced major bleeding by one-half and 30-day mortality by 17%.
Authors
Mehta SR; Granger CB; Eikelboom JW; Bassand J-P; Wallentin L; Faxon DP; Peters RJG; Budaj A; Afzal R; Chrolavicius S
Journal
Journal of the American College of Cardiology, Vol. 50, No. 18, pp. 1742–1751
Publisher
Elsevier
Publication Date
10 2007
DOI
10.1016/j.jacc.2007.07.042
ISSN
0735-1097